{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:52:33Z","timestamp":1753890753859,"version":"3.41.2"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T00:00:00Z","timestamp":1539043200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"DOI":"10.3389\/fendo.2018.00590","type":"journal-article","created":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T04:30:23Z","timestamp":1539059423000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Lung Recurrence of Papillary Thyroid Cancer Diagnosed With Antithyroglobulin Antibodies After 10 Years From Initial Treatment"],"prefix":"10.3389","volume":"9","author":[{"given":"David","family":"Viola","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Agate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora","family":"Molinaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Bottici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loredana","family":"Lorusso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Latrofa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liborio","family":"Torregrossa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Boldrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Ramone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Vitti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossella","family":"Elisei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2018,10,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1634\/theoncologist.12-1-20","article-title":"Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program","volume":"12","author":"Hayat","year":"2007","journal-title":"Oncologist"},{"key":"B2","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/nrendo.2012.38","article-title":"Advances in the follow-up of differentiated or medullary thyroid cancer","volume":"8","author":"Elisei","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1210\/jc.2009-1536","article-title":"Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question","volume":"95","author":"Elisei","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/0002-9343(94)90321-2","article-title":"Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer","volume":"97","author":"Mazzaferri","year":"1994","journal-title":"Am J Med"},{"key":"B5","unstructured":"Cancer Statistics Review NCI2018"},{"key":"B6","first-page":"1121","article-title":"Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma","volume":"83","author":"Spencer","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/S0300-9084(99)80096-0","article-title":"Serum and tissue thyroglobulin measurement: clinical applications in thyroid disease","volume":"81","author":"Pacini","year":"1999","journal-title":"Biochimie"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.1210\/jc.2011-1740","article-title":"Clinical review: clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC)","volume":"96","author":"Spencer","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1097\/MED.0000000000000092","article-title":"How sensitive (second-generation) thyroglobulin measurement is changing paradigms for monitoring patients with differentiated thyroid cancer, in the absence or presence of thyroglobulin autoantibodies","volume":"21","author":"Spencer","year":"2014","journal-title":"Curr Opin Endocrinol Diabetes Obes."},{"key":"B10","doi-asserted-by":"publisher","first-page":"4683","DOI":"10.1210\/jc.2008-0962","article-title":"Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma","volume":"93","author":"Kim","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","first-page":"346","DOI":"10.7326\/0003-4819-139-5_Part_1-200309020-00010","article-title":"Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens","volume":"139","author":"Chiovato","year":"2003","journal-title":"Ann Inter Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1097\/RLU.0b013e31825ae77b","article-title":"The additive clinical value of 18F-FDG PET\/CT in defining the recurrence of disease in patients with differentiated thyroid cancer who have isolated increased antithyroglobulin antibody levels","volume":"37","author":"Ozkan","year":"2012","journal-title":"Clin Nucl Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1007\/s12094-017-1782-3","article-title":"Prognostic value of change in anti-thyroglobulin antibodies after thyroidectomy in patients with papillary thyroid carcinoma","volume":"20","author":"Ernaga-Lorea","year":"2018","journal-title":"Clin Transl Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1089\/thy.2018.0080","article-title":"Changing trend of thyroglobulin antibodies in not 131I ablated differentiated thyroid cancer patients","volume":"28","author":"Matrone","year":"2018","journal-title":"Thyroid"},{"key":"B15","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1210\/jcem-72-1-209","article-title":"Thyroid ultrasonography helps to identify patients with diffuse lymphocytic thyroiditis who are prone to develop hypothyroidism","volume":"72","author":"Marcocci","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"B16","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3656-4","volume-title":"AJCC cancer staging handbook.","author":"Greene","year":"2002"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"B18","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3978\/j.issn.2227-684X.2014.12.06","article-title":"Recurrence of papillary thyroid cancer after optimized surgery","volume":"4","author":"Grant","year":"2015","journal-title":"Gland Surg"},{"key":"B19","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1200\/JCO.2014.56.8253","article-title":"Association between BRAF V600E mutation and recurrence of papillary thyroid cancer","volume":"33","author":"Xing","year":"2015","journal-title":"J Clin Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1530\/acta.0.1190373","article-title":"Thyroid autoantibodies in thyroid cancer: incidence and relationship with tumour outcome","volume":"119","author":"Pacini","year":"1988","journal-title":"Acta Endocrinol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1210\/jc.2011-2812","article-title":"Lymphocytic thyroiditis on histology correlates with serum thyroglobulin autoantibodies in patients with papillary thyroid carcinoma: impact on detection of serum thyroglobulin","volume":"97","author":"Latrofa","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B22","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1089\/thy.2015.0621","article-title":"Significance of low levels of thyroglobulin autoantibodies associated with undetectable thyroglobulin after thyroidectomy for differentiated thyroid carcinoma","volume":"26","author":"Latrofa","year":"2016","journal-title":"Thyroid"},{"key":"B23","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","year":"2014","journal-title":"Cell"},{"key":"B24","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.1210\/jc.2008-0607","article-title":"BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study","volume":"93","author":"Elisei","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1001\/jama.2013.3190","article-title":"Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer","volume":"309","author":"Xing","year":"2013","journal-title":"JAMA"},{"key":"B26","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00428-005-1236-0","article-title":"Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness","volume":"446","author":"Trovisco","year":"2005","journal-title":"Virchows Arch."},{"key":"B27","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1677\/erc.1.01119","article-title":"The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+\/I- targeting to the membrane","volume":"13","author":"Riesco-Eizaguirre","year":"2006","journal-title":"Endocr Relat Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1677\/ERC-07-0130","article-title":"BRAFV600E mutation, but not RET\/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer","volume":"15","author":"Romei","year":"2008","journal-title":"Endocr Relat Cancer"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2018.00590\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T04:30:43Z","timestamp":1539059443000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2018.00590\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,9]]},"references-count":28,"alternative-id":["10.3389\/fendo.2018.00590"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2018.00590","relation":{},"ISSN":["1664-2392"],"issn-type":[{"type":"electronic","value":"1664-2392"}],"subject":[],"published":{"date-parts":[[2018,10,9]]},"article-number":"590"}}